Biochips under COVID-19: a new stage of well-grounded development and accelerated translation.
Biochips under COVID-19: a new stage of well-grounded development and accelerated translation.
复制标题
COVID-19下的生物芯片：扎实发展、加速转化的新阶段
DOI：
10.1016/j.scib.2022.08.003
复制
发表时间：
2022-09-30
期刊：
影响因子：
18.9
通讯作者：
Cheng, Jing
中科院分区：
文献类型：
--
作者：
Liu, Jiajia;Xu, Youchun;Cheng, Jing
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）给全球医疗系统带来了沉重的负担，特别是在专业人员和专业实验室稀缺的发展中国家和欠发达国家。由于大规模检测需求增加以及冠状病毒疾病下疫苗和抗病毒药物的动物模型短缺，2019年随着2019冠状病毒病（COVID-19）大流行，用于在独立环境中快速诊断的芯片实验室（LoC）和用于体外研究的芯片器官（OoC）的开发和转化大大加快。特别是，2019冠状病毒病疫情再次确认了生物芯片平台在社区和分散式医疗系统诊断中的重要性，并大大加快了从研究到临床应用的转化。截至2022年4月15日，已有1135种基于生物芯片的SARS-CoV-2诊断方法通过欧洲认证（CE）认证（https：//covid-19-diagnostics.联合研究中心。EC. Europa. eu/），占COVID-19体外诊断（IVD）产品总数（2689）的42.2%（在线图S1）。此外，在美国食品和药物管理局（FDA）注册的274份SARS-CoV-2分子诊断检测的个人紧急使用授权（EUA）中，有100份（36.4%）（图S2在线）用于直接向消费者或家庭收集（https：//www. FDA. gov/medical-devices），在中国国家药品监督管理局（NMPA）注册的104种IVD技术中有27种（图S3在线）已被授权进行自助检测（https：//www. NMPA. gov.cn/search-result. html）。其中若干商品为持续对抗COVID-19作出重大贡献。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has placed a heavy burden on the global healthcare system, especially in developing and underdeveloped countries where professionals and specialized laboratories are scarce. And due to the increased demand for large-scale detection and the shortage of animal models for vaccines and antiviral drugs under the coronavirus disease 2019 (COVID-19) pandemic, the development and translation of lab-on-a-chip (LoC) for rapid diagnosis in a self-contained environment and organ-on-a-chip (OoC) for in vitro study have been greatly accelerated.Especially, the COVID-19 pandemic reaffirmed the importance of biochip platforms for diagnosis in community-based and decentralized medical systems, and greatly accelerated the translation from research to clinical application. As of April 15, 2022, 1135 SARS-CoV-2 diagnostic methods based on biochips had been authenticated by Conformitè Europëenne (CE) authentication (https://covid-19-diagnostics. jrc. ec. europa. eu/), which represents 42.2% of the total number (2689) of in vitro diagnostic (IVD) products for COVID-19 (Fig. S1 online). Moreover, 100 (36.4%) of 274 individual Emergency Use Authorizations (EUAs) for SARS-CoV-2 molecular diagnostic tests registered with the Food and Drug Administration (FDA) of the United States (Fig. S2 online) are for direct-to-consumer or home collection (https://www. fda. gov/medical-devices), and 27 of 104 IVD techniques registered with the National Medical Products Administration (NMPA) of China (Fig. S3 online) have been authorized for self-served testing (https://www. nmpa. gov. cn/datasearch/search-result. html). Several of these commodities generated significant contributions to the ongoing struggle against COVID-19.
登录
查看更多内容
影响因子：
39.3
作者：
Cheng L;Zhang X;Chen Y;Wang D;Zhang D;Yan S;Wang H;Xiao M;Liang T;Li H;Xu M;Hou X;Dai J;Wu X;Li M;Lu M;Wu D;Tian R;Zhao J;Zhang Y;Cao W;Wang J;Yan X;Zhou X;Liu Z;Xu Y;He F;Li Y;Yu X;Zhang S
通讯作者：
Zhang S
影响因子：
64.5
作者：
Fozouni P;Son S;Díaz de León Derby M;Knott GJ;Gray CN;D'Ambrosio MV;Zhao C;Switz NA;Kumar GR;Stephens SI;Boehm D;Tsou CL;Shu J;Bhuiya A;Armstrong M;Harris AR;Chen PY;Osterloh JM;Meyer-Franke A;Joehnk B;Walcott K;Sil A;Langelier C;Pollard KS;Crawford ED;Puschnik AS;Phelps M;Kistler A;DeRisi JL;Doudna JA;Fletcher DA;Ott M
通讯作者：
Ott M
影响因子：
28.1
作者：
Si L;Bai H;Rodas M;Cao W;Oh CY;Jiang A;Moller R;Hoagland D;Oishi K;Horiuchi S;Uhl S;Blanco-Melo D;Albrecht RA;Liu WC;Jordan T;Nilsson-Payant BE;Golynker I;Frere J;Logue J;Haupt R;McGrath M;Weston S;Zhang T;Plebani R;Soong M;Nurani A;Kim SM;Zhu DY;Benam KH;Goyal G;Gilpin SE;Prantil-Baun R;Gygi SP;Powers RK;Carlson KE;Frieman M;tenOever BR;Ingber DE
通讯作者：
Ingber DE
影响因子：
64.8
作者：
Karzbrun E;Khankhel AH;Megale HC;Glasauer SMK;Wyle Y;Britton G;Warmflash A;Kosik KS;Siggia ED;Shraiman BI;Streichan SJ
通讯作者：
Streichan SJ
影响因子：
8.4
作者：
Zhu, Yunzeng;Meng, Xiangrui;Cheng, Jing
通讯作者：
Cheng, Jing